Combining metabolic and protein engineering of a terpenoid biosynthetic for overproduction and selectivity control

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1073/pnas.1006138107">http://dx.doi.org/10.1073/pnas.1006138107</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>National Academy of Sciences</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Accessed</td>
<td>Sun Apr 24 20:51:26 EDT 2016</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/73144">http://hdl.handle.net/1721.1/73144</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td></td>
</tr>
</tbody>
</table>

Combining metabolic and protein engineering of a terpenoid biosynthetic pathway for overproduction and selectivity control


A common strategy of metabolic engineering is to increase the endogenous supply of precursor metabolites to improve pathway productivity. The ability to further enhance heterologous production of a desired compound may be limited by the inherent capacity of the imported pathway to accommodate high precursor supply. Here, we present engineered diterpenoid biosynthesis as a case where insufficient downstream pathway capacity limits high-level levopimaradiene production in Escherichia coli. To increase levopimaradiene synthesis, we amplified the flux toward isopentenyl diphosphate and dimethylallyl diphosphate precursors and reprogrammed the rate-limiting downstream pathway by generating combinatorial mutations in geranylgeranyl diphosphate synthase and levopimaradiene synthase. The mutant library contained pathway variants that not only increased diterpenoid production but also tuned the selectivity toward levopimaradiene. The most productive pathway, combining precursor flux amplification and mutant synthases, conferred approximately 2,600-fold increase over production of levopimaradiene. Levopimaradiene synthesis was increased when GGPPS expression was coupled with the diterpenoid gateway precursor of the pharmaceutically important plant-derived ginkgolides (25–28). The biosynthesis of levopimaradiene from simple carbon sources (glucose or glycerol) starts from the formation of the precursors isopentenyl diphosphate (IPP), and dimethylallyl diphosphate (DMAPP) derived from the 2-C-methyl-D-erythritol-4-phosphate (MEP) pathway in E. coli. Geranylgeranyl diphosphate synthase (GGPPS) then catalyzes the condensation of IPP and DMAPP to the linear diphosphate intermediate geranylgeranyl diphosphate (GGPP). In the final step, levopimaradiene synthase (LPS) catalyzes the conversion of GGPP to levopimaradiene via a complex reaction cascade of cyclization, rearrangement, and proton transfers (Fig. 1A). The promiscuous function of LPS also results in the formation of isomeric side products such as abietadiene, sandaracopimaradiene, and neoabietadiene (29, 30) (Fig. 1B). The functional expression of codon-optimized genes encoding for GGPPS and LPS in E. coli only generated minute quantities of levopimaradiene. Levopimaradiene synthesis was increased when GGPPS–LPS expression was coupled with the systematic amplification of genes in the upstream MEP pathway to elevate flux toward IPP and DMAPP; however, titers remained low. We postulated that the threshold of levopimaradiene

Sequence analysis of these enzymes showed that they are paralogous proteins evolved through gene duplications that subsequently diverged in functional roles to catalyze the formation of different terpenoid structures (16, 17, 19). Particularly, terpenoid synthases generate enzyme-bound carbocation intermediates that undergo a cascade of rearrangements and quenchings of carbocations to create structural diversity (20). These enzymes are highly promiscuous (21), and the functional promiscuity is often associated with unwanted product formation and poor catalytic properties (22). Thus in an engineered terpenoid pathway, these enzymes lead to low metabolic fluxes and large byproduct losses, limiting yield improvement of the desired product molecules. In some cases, the buildup of intermediate metabolites elicits stress responses detrimental to cell growth (23, 24). Thus, the ability to tune a heterologous terpenoid pathway at regulatory nodes would be a valuable approach both to confer an overproduction phenotype and to minimize toxicity in microorganisms.

In the present work, we engineered Escherichia coli to produce levopimaradiene, the diterpenoid gateway precursor of the pharmaceutically important plant-derived ginkgolides (25–28). The biosynthesis of levopimaradiene from simple carbon sources (glucose or glycerol) starts from the formation of the precursors isopentenyl diphosphate (IPP), and dimethylallyl diphosphate (DMAPP) derived from the 2-C-methyl-D-erythritol-4-phosphate (MEP) pathway in E. coli. Geranylgeranyl diphosphate synthase (GGPPS) then catalyzes the condensation of IPP and DMAPP to the linear diphosphate intermediate geranylgeranyl diphosphate (GGPP). In the final step, levopimaradiene synthase (LPS) catalyzes the conversion of GGPP to levopimaradiene via a complex reaction cascade of cyclization, rearrangement, and proton transfers (Fig. 1A). The promiscuous function of LPS also results in the formation of isomeric side products such as abietadiene, sandaracopimaradiene, and neoabietadiene (29, 30) (Fig. 1B). The functional expression of codon-optimized genes encoding for GGPPS and LPS in E. coli only generated minute quantities of levopimaradiene. Levopimaradiene synthesis was increased when GGPPS–LPS expression was coupled with the systematic amplification of genes in the upstream MEP pathway to elevate flux toward IPP and DMAPP; however, titers remained low. We postulated that the threshold of levopimaradiene
production was limited by inherent GGPPS–LPS capacity. To overcome this constraint, we adopted the principle of molecular reprogramming through engineering combinatorial mutations of the GGPPS–LPS pathway. This approach was inspired by natural systems, in which biosynthetic pathways undergo molecular reprogramming processes (e.g. via mutations of transcription regulators and enzymes) to accommodate important changes in metabolite concentrations (31–34). By combining protein and metabolic engineering, we achieved approximately 2,600-fold improvements in metabolite concentrations (31 regulators and enzymes) to accommodate important changes in metabolic reprogramming processes (e.g. via mutations of transcription systems, in which biosynthetic pathways undergo molecular reprogramming).

**Results and Discussion**

**Levopimaradiene Production Improvement via Precursor Pathway Amplification.** The initial attempt to synthesize levopimaradiene from *E. coli* by coexpressing codon-optimized genes encoding for GGPPS and LPS resulted in only a small amount of levopimaradiene, 0.15 mg/L (Table S1), with no detectable amount of the related isomers produced by LPS. The first step taken to improve productivity was a metabolic engineering approach via incremental overexpression of the bottleneck enzymatic steps in the MEP pathway, namely *dxs, idi, ispD*, and *ispF* (Fig. 1A). Indeed, this approach improved levopimaradiene production (Table S1). The highest production of approximately 92 mg/L was achieved by inclusion of approximately 5 additional copies of the MEP pathway genes. At this level, the levopimaradiene isomers abietadiene, sandaracopimaradiene, and neoabietadiene (Fig. 1B) were also identified in the culture, at product fractions of 11%, 2%, and trace amounts, respectively (Fig. S1). However, further increasing the MEP pathway from approximately 5 to approximately 10 copies was not accompanied by additional increases in levopimaradiene production. In fact, the titer was lower (approximately 23 mg/L) than when MEP pathway was amplified by approximately 5-fold (Table S1). These results demonstrated that stepwise improvement of precursor flux, a strategy commonly employed in metabolic engineering, did not yield an incremental amplification of terpenoid molecules.

Hence, we postulated that the efficiency of the regulatory node in terpenoid biosynthesis, the GGPPS–LPS (prenyltransferase–terpenoid synthase) portion of the pathway, is rate-limiting under high IPP and DMAPP precursor flux (16–18, 20–22). Quantitative RT-PCR confirmed that higher MEP pathway transcript levels were achieved with 10-fold amplification of the MEP pathway, likely resulting in a buildup of toxic intermediates that negatively affected overall pathway flux (23). Thus, we set out to reprogram GGPPS and LPS to develop mutant pathways that confer high-level levopimaradiene production in the 10-copy MEP pathway background.

**Probing the Putative Binding Pocket in LPS to Design Improved Variants.** Fully combinatorial strategies to search for important mutations in LPS are impractical due to the lack of a suitable high-throughput screen. To circumvent this limitation, we first constructed a homology structure for the second active site of ginkgolides. Coproducts of LPS include abietadiene, neoabietadiene, and sandaracopimaradiene that stem from the different deprotonation patterns throughout intermediates in the reaction cascade.

**Fig. 1.** (A) Engineering levopimaradiene synthesis in *E. coli*. A plant-derived pathway was constructed by introducing *T. chinensis* ggpps and *G. biloba* lps codon-optimized genes. To amplify the endogenous precursor pools of GGPPS substrates (IPP and DMA), copy numbers of rate-limiting steps (*dxs, idi, ispD, ispF*) in the MEP pathway were amplified by additional episomal expression. (B) General reaction mechanism of “LPS-type” enzymes. Levopimaradiene, the major product of *G. biloba* LPS is the gateway precursor of ginkgolides. Coproducts of LPS include abietadiene, neoabietadiene, and sandaracopimaradiene that stem from the different deprotonation patterns throughout intermediates in the reaction cascade.
and I855L, based on residues in _A. grandis_ and _P. abies_ AS; whereas Y700H, A727S and V731L were created based on _P. abies_ ISO. Alanine was used to replace Asn769 and Glu777 because these amino acids are conserved throughout LPS, AS, and ISO (Fig. 2).

The preengineered _E. coli_ (with the addition of approximately 10 copies of the MEP pathway genes) expressing the wild-type GGPPS provided an in vivo screening system for titer and product distribution changes by the LPS mutations. We observed that the profiles of diterpenoid product distribution resulting from expressing LPS mutants M593I, C618N, L619F, A620T, L696Q, K723S, V731L, N838E, and I855L were similar to expression of wild-type LPS (within 50%). However, diterpenoid production levels were notably altered by expressing mutants M593I, C618N, L619Q, K723S, V731L, N838E, and I855L (Fig. 2 and Table S2). The highest total diterpenoid production increase (approximately 3.7-fold) was mediated by expressing LPS M593I. In all cases, expression of these mutants did not significantly affect product distribution. Expression of LPS mutant Y700H, however, resulted in significant alteration of diterpenoid product distribution by abolishing abietadiene synthesis and increasing sandaracopimaradiene proportion (Fig. 2). Although a single mutation in _P. abies_ AS, Y868H (corresponding to Tyr700 in LPS) did not result in product selectivity changes in vitro, it promoted isopimaradiene synthesis when combined with another mutation (Y868H/A713S) (38); hence Tyr700 may play an important role in mediating the evolvability of LPS-type enzymes. Additionally, the expression of the A729G mutant resulted in the exclusive production of sandaracopimaradiene; however, it was concomitant with a reduction in productivity of approximately 98% (Fig. 2). Finally, diterpenoid production was not observed in systems expressing LPS A727S, N769A, and G854T were also not significantly changed compared to wild-type LPS (within 50%).

Although the preliminary mutational enrichment of tunable LPS residues to identify variants conferring increased productivity (Fig. 3) was not detected (ND). Numbers indicate percentage of each isomer (1-levopimaradiene; 2-abietadiene; 3-sandaracopimaradiene).

**Fig. 2.** Summary of LPS mutations and the impact with respect to product distribution and producton of the engineered pathway. Trace amount (TA), not detected (ND). Numbers indicate percentage of each isomer (1-levopimaradiene; 2-abietadiene; 3-sandaracopimaradiene).

From the saturation mutagenesis library of Met593, we found two substitutions that conferred significant productivity improvement (Fig. 3A and Table S3). In addition to isoleucine, which was discovered in the phylogenetic-based mutation, the replacement with leucine, another hydrophobic residue similar in size as methionine, increased diterpenoid productivity by approximately 2-fold without significantly changing product distribution (Fig. 3A). Based on the structural significance of this position, this productivity improvement appeared to be caused by the disruption of H-bonding at the end of the binding pocket, thus increasing the flexibility of the cavity to better fit the CPP substrate. Therefore, the M593I mutation likely resulted in the highest production increase (approximately 3.7-fold) because isoleucine is the most hydrophobic amino acid. Substitutions with smaller residues than methionine only yielded moderate production improvement (<2-fold in the case of cysteine, serine, and threonine), and were disruptive in the case of alanine, glycine, and valine. Furthermore, substitutions with amino acids longer than five heavy atoms and those with bulky rings such as phenylalanine, tyrosine, and tryptophan also consistently decreased or abolished activity. These trends are consistent with the requirement for the substrate to have an unobstructed cyclization pocket, as the center of the bend is proximal to this residue. Moreover, replacements with hydrophilic amino acids such as aspartic acid, glutamic acid, lysine, and arginine also generally reduced productivity possibly because their ability to form their own H-bonding may reduce the capacity of the binding pocket.

We also found that the replacement of Tyr700 with phenylalanine, methionine, and tryptophan improved productivity up to approximately 5-fold (Fig. 3B and Table S4). The reaction cascade toward the formation of abietenyl cation requires an energetically unfavorable transition from a tertiary to a secondary carbocation (30). Therefore it was postulated that the latter species is stabilized by the ionic interaction with the paired diphosphate anion that is chelated by the magnesium ion (37). Tyr700 is located within close proximity to the magnesium binding site, thus the absence of the hydroxyl group in amino acids that are similar to tyrosine may allow the repositioning of the magnesium closer to the aspartate-rich region, hence increasing reaction efficiency by improving the chelation of the diphosphate group. A few mutations, i.e. replacements with aspartic acid, histidine, proline, arginine, and lysine, abolished abietadiene synthesis in the product mixture, and conferred a decrease in productivity (Fig. 3B). The replacement with positively charged residues or a helix breaker (proline) might cause a misalignment of the diphosphate anion that impaired catalysis or prevented the deprotonation of abietenyl cation at carbon position I (Fig. 1B) to create abietadiene.

Finally, the sampling of all amino acid substitutions of Ala620 revealed that only replacement with residues similar to alanine (small or hydrophilic) (cysteine, glycine, serine, and threonine) as well as valine retained LPS activity; whereas other substitutions were destructive or deleterious (Fig. 3C and Table S5). A few destructive mutations (replacements with aspartic acid, leucine, asparagine) also destabilized abietenyl deprotonation to yield abietadiene. Therefore, Ala620 in LPS did not appear to control product selectivity and productivity in LPS, yet it was important for catalysis.

Combining Beneficial Mutations in LPS to Further Improve Productivity. In laboratory experiments, the beneficial effects of single
mutations are often additive (39, 40). Therefore, the production improvement resulting from expressing the LPS M593I variant encouraged us to explore the effect of this beneficial mutation in combination with saturation mutagenesis of Tyr700. As shown in Fig. 3D (Table S6), this combination successfully integrated the advantageous properties of the individual mutations, resulting in one variant (M593I/Y700F) that increased diterpenoid titer by approximately 10-fold over the expression of the wild-type enzyme without significant changes in product distribution. Interestingly, the expression of most LPS variants carrying the double mutations resulted in the reduction of abietadiene proportion (Fig. 3D). In two variants, M593I/Y700A and M593I/Y700C, the reduction of abietadiene was complemented by an increase in levopimaradiene, resulting in mixtures that contained up to 97% levopimaradiene. The combinations of M593I with Y700A and Y700C also conferred productivity improvements of approximately 6.3- and approximately 5.8-fold, respectively. Thus, it appeared that these mutations facilitated the stabilization of the intermediates that led to favoring abietenylation intermediate formation yet prevented proton extraction from route f (Fig. 1B).

It is noteworthy that using the M593I mutant LPS as a parent for the subsequent saturation mutagenesis only produced three variants that decreased or abolished diterpenoid productivity (Fig. 3D). In contrast, previous saturation mutagenesis of Tyr700 resulted in five pathway variants that decreased/abolished diterpenoid production (Fig. 3B). Although a single M593I mutation was rendered neutral with respect to product selectivity, this mutation restored LPS activity upon subsequent defective mutations by aspartic acid and histidine replacement at residue 700. Thus M593I appeared to facilitate subsequent mutational robustness, a paradigm of neutral genetic drift (39).

Engineering Functional Mutations in GGPPS to Further Increase Diterpenoid Production. We next opted to mutate GGPPS, with the goal of further increasing pathway productivity. Although the structure of a plant GGPPS of angiosperm origin (from Sinapis alba) is available (41), the crystal structure for a gymnosperm GGPPS has not been solved. Furthermore, the folding similarity of gymnosperm GGPPS enzymes and their angiosperm analogs is not known. Despite catalyzing essentially the same enzymatic reaction, GGPPS enzymes are known to exhibit wide structural diversity among organisms (41). Therefore, based on secondary structure analysis (42), the notable division of gymnosperm from angiosperm GGPPS enzymes may imply significant tertiary fold differences. In the case of T. canadensis GGPPS, its amino acid sequence only exhibited approximately 56% homology with that of S. alba GGPPS, with frequent gaps throughout the entire sequence (Fig. S3). As a result, the lack of a suitable structural guide prompted us to devise a random approach to mutate T. canadensis GGPPS. To enable a facile high-throughput screening method for isolating improved GGPPS variants, we utilized a lycopene biosynthetic pathway consisting of crtB and crtI as a colorimetric reporter (Fig. 4A). In this system, the expression of wild-type GGPPS resulted in colonies with light red coloration. Improved GGPPS variants from the mutagenesis were identified by the improvement of lycopene production in the cell, as determined by red coloration.

We isolated fifteen ggpps variants from colonies exhibiting red coloration. To assess the potential for improving levopimaradiene production in vivo, the fifteen mutant GGPPS isolates were coexpressed with the high-producing LPS M593I/Y700F mutant in the preengineered E. coli strain. Five GGPPS variants did not confer a levopimaradiene increase, indicating false positives obtained from the colorimetric screening. However, the coexpression of ten GGPPS mutants resulted in diterpenoid production improvement (Fig. 4B). The expression of mutant G10 resulted in the highest diterpenoid production increase of approximately 1.7-fold over the pathway harboring the wild-type GGPPS and the LPS M593I/Y700F, an equivalent of an approximately 17.7-fold increase over the pathway harboring wild-type GGPPS and LPS (Fig. 4B and Table S7). Sequence analysis of G10 revealed that two positions were mutated, namely S239C and G295D (Fig. S4). Amino acid alignment with GGPPS sequences from other plants (43) showed that most beneficial mutations are located in the region in between the two highly

---

**Fig. 3.** Characteristics (productivity and product distribution) of the preengineered strains expressing wild-type ggpps and lps saturation mutagenesis library of: (A) Met593, (B) Tyr700, (C) Ala620, and (D) Tyr700 using lps M593I. In the product distribution charts, gray bars, orange bars, white bars represent proportion of levopimaradiene, abietadiene, and sandaracopimaradiene in the product mixture, respectively. Two toned (white and light gray) bars represent nil production. WT represents the preengineered strain expressing wild-type ggpps and lps.
were then coexpressed with improved lycopene production (red colonies) were isolated. These variants represent the strain expressing the wild-type noid production assay. (Table S7). The performance of the preengineered E. coli levopimaradiene pathway consisting of GGPPS S239C/G295D and LPS M593I/Y700F increased levopimaradiene production approximately 2,600-fold over the expression of wild-type GGPPS and LPS alone (Table S7).

**Levopimaradiene Overproduction in Controlled Culture Conditions.** The performance of the preengineered E. coli strain expressing the highest-producing levopimaradiene pathway consisting of GGPPS S239C/G295D and LPS M593I/Y700F was assessed in bioreactors under controlled conditions. The total diterpenoid titer reached a maximum of approximately 800 mg/L in 168 h, and levopimaradiene constituted approximately 700 mg/L (Fig. 5A). Using this engineered strain, 10 g/L glycerol was almost depleted after 56 h. Therefore 3 g/L glycerol was introduced into the culture every 8 h after this time point (Fig. 5B). Despite the relatively rapid consumption of glycerol, acetate only accumulated below 1 g/L throughout the cultivation. Overall, this experiment demonstrated that the production improvement obtained from the new pathway translated well toward larger cultivation.

**Materials and Methods**

**Cloning and pathway construction.** All cloning procedures were carried out in E. coli strain DH5α (Invitrogen), and pathway engineering was performed in E. coli MG1655 Δ(enaA, recA) strains (SI Appendix). Mutants were custom-synthesized (DNA 2.0) to incorporate E. coli codon bias, remove restriction sites for cloning purposes, and establish an approximately 50% GC-content. All strains carried the native chromosomal copy of the MEP pathway. Additional copies of pathway genes were inserted as operon dxs-idi-isop-fdh under a Trc promoter. The single copy MEP strain was constructed by chromosomal localization of the MEP pathway and higher copy numbers were achieved through plasmid-based expression (SI Appendix and Table S8). Relative expression levels were verified through quantitative RT-PCR.

**Culture Growth and Library Analysis.** Single transformants of preengineered E. coli strains expressing pTrcGGPPS-LPS, or their mutant variants were cultivated for 18 h at 30 °C in LB. For library characterization, these preinocula were used to seed fresh 2 mL cultures at a starting A600 of 0.1 in rich medium (SI Appendix). Scale-up experiments (1-L cultures) were done in 3-L bioreactors (SI Appendix). To minimize the loss of diterpenoids due to air-stripping, 20% dodecane was added into the culture. The diterpenoid production was characterized by GC-MS analysis (SI Appendix).

**Molecular Modeling.** The homology model of LPS was built based on the structure of 5-epi-aristolochene synthase (48) [EAS (Protein Data Bank ID code 5TA7)]. Sequence alignment (Fig. S5) was performed with the ClustalW (49) method with standard gap penalties. Whereas LPS contains 323 residues in excess of EAS, they aligned almost exclusively at the proximity of the

**Fig. 5.** Cultivation of the E. coli strain overexpressing the MEP pathway and the “reprogrammed” plant-derived pathway constituting GGPPS S239C/G295D and LPS M593I/Y700F mutants. (A) Diterpenoid production curves. Total diterpenoid, levopimaradiene, abietadiene, and sandaracopimaradiene are in circles, squares, triangles, and crosses, respectively. (B) Feed, fermentative by-product, and biomass curves. Glycerol, acetate, and cell density are in triangles, diamonds, and circles, respectively. Inverse triangle denotes the time point where 3 g of glycerol was added every 8 h.

**Conclusions**

Efforts to increase terpenoid production in E. coli previously focused on (i) overexpression of pathway enzymes, and (ii) optimizing the expression of enzymes by codon bias (7, 23, 45, 46). However, these approaches, which both aim to increase enzyme concentration to increase pathway flux, are still limited by the inherent low enzyme activity and specificity of the terpenoid pathways. Thus, in addition to metabolic engineering, the molecular reprogramming of key metabolic nodes such as prenyl transferase (GGPPS) and terpenoid synthase (LPS) though protein engineering is required to achieve substantial overproduction of a desired terpenoid product. Our approach has wide applicability not only in engineering of terpenoid pathways but also in many other secondary metabolic pathways, especially those with promiscuous enzymes that act as regulatory nodes. Our results also dispute the current notion that the MEP pathway is not effective for high-level production of terpenoid molecules (23, 47). In fact, the stoichiometry of the bacterial MEP pathway is 12–14% more efficient in consuming glucose or glycerol without redox imbalance compared to the eukaryotic mevalonate pathway for IPP/DMAPP synthesis. In a broader sense, because terpenoid pathways lead to compounds used in flavors, cosmetics, and potentially biofuels, our engineering approach is directly applicable for the high-level production of many commercially important compounds using microbial biotechnology.
second active side (toward the C-terminus), with a virtually gapless alignment. The CHARMM molecular modeling software (SO, 51) with the CHARMM27 parameter set was used to mutate residues. Partial atomic charges needed for the substrate were obtained quantum mechanically with the Gaussian program using the 6-31G* basis set. Fifteen residues within a 10 Å distance from the substrate that contours the binding pocket were determined by using normal molecular dynamics (VMD) (52) (http://www.ks.uiuc.edu/Research/vmd/).

Mutant Library Generation and Screening. The introduction of point mutations and saturation mutagenesis in Psp was performed using QuikChange II XL (Stratagene). Nucleotide changes were set by custom designed oligonucleotides (Table 5B). Subsequent to sequencing to verify nucleotide changes, the first variants were used to replace the wild-type Psp in pTrcGPPS-LPM and subjected to expression in the engineered E. coli for production analysis. The random mutagenesis library of ggpps was created by error-prone (EP) PCR at low mutation rate using GeneMorph II (Stratagene). A pool of plasmid pTrcGGPPS-CRT was isolated from more than approximately 10^4 transformants of E. coli DH10B. The plasmid library was then used to transform the E. coli strain overexpressing the MEP pathway for colorimetric screening.

Colonies that displayed bright red coloration were isolated after incubation at 25 °C for 3 d (as visualized on LB containing 75 μg/mL ampicillin and 25 μg/mL chloramphenicol). Following plasmid extraction and sequencing, the mutant ggpps genes were used as a pool in the second round of EP PCR. As a control, the integration of wild-type ggpps into the lycopene pathway gave rise to orange colored transformants. The iteration of mutation and screening was stopped after the second round of mutant collection, as no colony that displayed higher red coloration was identified in the third round of EP PCR.

ACKNOWLEDGMENTS. We thank S.-H. Yoon (Prather lab) for the construction of E. coli MG1655Δ (ΔnaA, recA). We also thank W. Runghuphan, S. O’Connor [Department of Chemistry, Massachusetts Institute of Technology (MIT)], C. Martin, T. L. To [Department of Chemical Engineering, MIT], and D. Groshoff (Harvard University) for constructive discussions, and critical reading of this manuscript. Research in the Prather laboratory is supported by the Camille and Henry Dreyfus Foundation New Faculty Award, and the MIT Energy Initiative (Grant 6917278). Research in the Stephanopoulos laboratory is supported by the Singapore–MIT Alliance and the US National Institutes of Health (Grant R01-GM085323-01A1). Research in the Tidor laboratory is supported by the US National Institutes of Health (Grant GM065418).